Astria Therapeutics Inc
$ 12.95
-0.23%
26 Dec - close price
- Market Cap 739,249,000 USD
- Current Price $ 12.95
- High / Low $ 12.96 / 12.89
- Stock P/E N/A
- Book Value 2.44
- EPS -2.14
- Next Earning Report 2026-03-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.27 %
- ROE -0.43 %
- 52 Week High 13.29
- 52 Week Low 3.56
About
None
Analyst Target Price
$24.60
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-12 | 2025-08-12 | 2025-05-07 | 2025-03-03 | 2024-11-11 | 2024-08-12 | 2024-05-09 | 2024-03-04 | 2023-11-13 | 2023-08-07 | 2023-05-11 | 2023-03-22 |
| Reported EPS | -0.55 | -0.57 | -0.58 | -0.44 | -0.42 | -0.43 | -0.38 | -0.94 | -0.63 | -0.45 | -0.4 | -0.72 |
| Estimated EPS | -0.42 | -0.49 | -0.4775 | -0.4517 | -0.42 | -0.38 | -0.36 | -0.78 | -0.49 | -0.49 | -0.55 | -0.71 |
| Surprise | -0.13 | -0.08 | -0.1025 | 0.0117 | 0 | -0.05 | -0.02 | -0.16 | -0.14 | 0.04 | 0.15 | -0.01 |
| Surprise Percentage | -30.9524% | -16.3265% | -21.466% | 2.5902% | 0% | -13.1579% | -5.5556% | -20.5128% | -28.5714% | 8.1633% | 27.2727% | -1.4085% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-05 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.5543 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ATXS
2025-12-20 21:09:04
Monteverde & Associates PC, a class action firm, is investigating several mergers for potential shareholder claims. These include the sales of Astria Therapeutics, Inc. (ATXS) to BioCryst Pharmaceuticals, Inc., Middlefield Banc Corp. (MBCN) to Farmers National Banc Corp., and Semrush Holdings, Inc. (SEMR) to Adobe Inc. Shareholders of these companies are encouraged to contact the firm for more information regarding their rights and the proposed transaction terms.
2025-12-13 17:02:00
This article provides a technical analysis of Astria Therapeutics Inc. (NASDAQ: ATXS) based on AI models from Stock Traders Daily. It highlights weak near-term sentiment but strong mid- and long-term signals, and outlines three distinct trading strategies for different risk profiles. The analysis includes support and resistance levels across multiple timeframes and emphasizes the predictive AI's ability to offer real-time signals and risk management for institutional and individual traders.
2025-12-11 12:09:34
BioCryst Pharmaceuticals announced that Dr. Nancy J. Hutson will retire from its Board of Directors and step down as board chair, with Vincent J. Milano elected as her successor. This transition is expected to occur upon the closing of BioCryst’s proposed acquisition of Astria Therapeutics or at the company's 2026 annual meeting. The announcement comes amidst other company developments, including Q3 2025 earnings results and antitrust clearance for the Astria Therapeutics acquisition.
2025-12-10 23:08:54
JPMorgan Chase & Co. significantly increased its stake in Astria Therapeutics, Inc. (NASDAQ:ATXS) by 4,607.1% in the second quarter, now owning 1,696,071 shares valued at $9.09 million. This comes as Astria Therapeutics reported disappointing Q results, missing EPS and revenue estimates. Despite mixed analyst ratings, institutional investors largely control the company's shares.
2025-12-07 10:22:04
Panagora Asset Management Inc. recently acquired a new position of 98,458 shares in Astria Therapeutics, Inc. (NASDAQ:ATXS) valued at $528,000. Other institutions like JPMorgan Chase & Co. and ADAR1 Capital Management LLC significantly increased their stakes, leading to institutional ownership of 98.98%. Despite a consensus "Hold" rating from analysts with a $24.50 price target, the biotechnology company recently missed EPS and revenue estimates, and its stock trades around $12.93.
2025-12-07 00:09:53
Affinity Asset Advisors LLC has acquired 300,000 shares of Astria Therapeutics, Inc. (NASDAQ:ATXS), a new position valued at approximately $1.61 million, meaning institutional investors now own 98.98% of the company. Despite recent downgrades from analysts and missed quarterly earnings estimates, the stock is trading near its 52-week high with a market cap of about $738 million. The consensus rating from analysts is "Hold" with an average target price of $24.50.
